Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from ITCC and SIOPEN"/>

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from ITCC and SIOPEN

1 Sept

Written By Carla Aguilera

Full title: Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav Š, Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJ.

Eur J Cancer. 2020 Sep;136:52-68. doi: 10.1016/j.ejca.2020.05.010. Epub 2020 Jul 9. PMID: 32653773.

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma